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Orexin deficiency results in the sleep disorder narcolepsy in many mammalian species, 
including mice, dogs, and humans, suggesting that the orexin system is particularly 
important for normal regulation of sleep/wakefulness states, and especially for 
maintenance of wakefulness. This review discusses animal models of narcolepsy; the 
contribution of each orexin receptor subtype to the narcoleptic phenotypes; and the 
etiology of orexin neuronal death. It also raises the possibility of novel therapies 




A series of studies have suggested that loss of the hypothalamic neurons producing the 
orexin (hypocretin) neuropeptides causes narcolepsy in humans and other mammalian 
species, highlighting roles of this neuropeptide in the regulation of sleep and 
wakefulness(1). The deficiency of orexin signaling in narcolepsy-cataplexy 
unequivocally shows that this neuropeptide system plays a physiologically essential role 
in the regulation of sleep and wakefulness, especially in the maintenance of long, 
consolidated waking periods. This chapter discusses the relationship between orexin-
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deficiency and narcolepsy; why orexin deficiency causes narcolepsy; and the 
therapeutic potential of drugs that target orexin receptors for treating insomnia, 
narcolepsy and other sleep disorders.  
 
What is narcolepsy? 
Narcolepsy is a debilitating neurological disorder, characterized by instability of 
sleep/wakefulness states and pathological intrusions of REM sleep-related events into 
wakefulness. It affects approximately 1 in 2,000 individuals in the United States(2). 
Males and females are equally affected. The onset of the disease usually occurs during 
adolescence, suggesting that narcolepsy is an acquired, not an innate, condition. 
However, although most cases of narcolepsy occur sporadically, familial clustering may 
be observed; the risk of a first-degree relative of a narcoleptic developing narcolepsy is 
10-40 times higher than in the general population(3). The development of the disease 
seems to involve both environmental and genetic factors.  25 to 31% of monozygotic 
twins were reported to be concordant for narcolepsy(2). 
The most disruptive symptom of the disorder is excessive daytime sleepiness, or 
daytime hypersomnia (an insurmountable urge to sleep), which often results in falling 
asleep at inappropriate times and situations (‘sleep attacks’). Patients with narcolepsy 
have a three-fold increased risk of motor vehicle accidents from lapses in attention, lack 
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of alertness, and dozing off. The latency for rapid eye movement (REM) sleep is 
markedly reduced in narcolepsy patients, and REM sleep is sometimes observed shortly 
after sleep onset (‘sleep-onset REM periods’). Nocturnal sleep is often disturbed by 
sleep fragmentation and premature awakenings. Other symptoms include hypnagogic 
hallucinations, vivid dreaming, and sleep paralysis which occurs as patients fall asleep 
or upon awakening. 
Narcolepsy patients often suffer from attacks of “cataplexy” - sudden episodes 
of muscle weakness, ranging from facial weakness and slurred speech to complete 
collapse from widespread weakness. Cataplexy is usually triggered by strong emotional 
stimuli. Unlike sleep attacks, consciousness is preserved during cataplexy. In the 
International Classification of Sleep Disorders, narcolepsy accompanied by cataplexy is 
referred to as “narcolepsy with cataplexy”, while that without cataplexy is termed 
“narcolepsy without cataplexy” (4). 
 
Dog and Rodent Models of Narcolepsy 
Animal models first suggested the involvement of orexin-dysfunction in narcolepsy. 
Using a forward genetics approach, Mignot and colleagues  found that dogs with a 
mutation in the orexin 2 receptor are remarkably similar to human narcolepsy 
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patients(5). As in human narcolepsy, narcoleptic dogs exhibit cataplexy (elicited by the 
presentation of food), sleepiness (i.e. reduced sleep latency), and SOREMPs(6). These 
findings suggested that loss of orexin-2 receptor-mediated signaling can produce a 
narcolepsy phenotype. 
Mouse models also showed a relationship between narcolepsy and orexin system 
abnormalities. At first, Yanagisawa’s group found that Orexin-/- mice showed a 
phenotype remarkably similar to human narcolepsy(7).Subsequently, orexin neuron-
ablated (orexin/ataxin-3-transgenic) mice or Oxr-1-/-;Oxr-2-/- (double-receptor-deficient) 
mice were shown to have very similar phenotypes that have strong parallels to the 
human narcolepsy with behavioral arrests very similar to cataplexy, direct transitions 
from wakefulness to REM sleep, and highly fragmented sleep-wake cycles(8-10), all of 
which are important features of narcolepsy. Oxr-2-/- mice also show a narcolepsy 
phenotype, though it is milder than that of orexin-/- mice, orexin neuron-ablated 
(orexin/ataxin-3-transgenic) mice, Oxr-1-/-;Oxr-2-/- mice(9). 
 
Human Narcolepsy and Orexin Deficiency 
The link between orexin dysfunction and narcolepsy has been subsequently confirmed 
and established by studies on human narcolepsy patients. First, nine human narcolepsy 
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patients were shown to have very low levels of orexin A in their cerebrospinal fluid 
(CSF) as compared with healthy controls (11). Postmortem brain studies of human 
narcolepsy patients subsequently showed no detectable levels of orexin peptides in the 
cortex and pons, in which orexinergic projections are normally found (Figure 1A), and 
an 80-100% reduction in the number of neurons containing detectable prepro-orexin 
mRNA or orexin-like immunoreactivity in the hypothalamus(12, 13).  
Approximately 90% of patients with narcolepsy with cataplexy have decreased 
orexin A levels in cerebrospinal fluid(14) (Figure 1B). Accordingly, a low CSF level of 
orexin A (less than 110 pg/ml) is now one of the diagnostic criteria for narcolepsy-
cataplexy according to the 2nd edition of the International Classification of Sleep 
Disorders (ICSD-2) (4).  Especially, narcolepsy with cataplexy is thought to be more 
closely related to orexin deficiency as compared with narcolepsy without cataplexy. 
Because of its strong association with certain human leukocyte antigen (HLA) 
alleles(15), it has long been speculated that narcolepsy results from an autoimmune-
mediated mechanism. Recently, Tribbles homolog 2 (Trib2) was reported as a candidate 
antigen involved in the destruction of orexin neurons (16). Trib2 was shown to be 
abundantly expressed in orexin neurons, and levels of Trib2-specific antibodies were 
much higher in patients with narcolepsy, especially shortly after the disease onset, 
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although it is still unknown if Trib2-specific antibodies are directly involved in cell 
death, or if the antibody production is a consequence of cell damage by other unknown 
mechanisms(17).  
Recent large scale genome wide association studies (GWAS) showed that susceptibility 
to narcolepsy is associated with single nucleotide polymorphisms (SNPs) in the T-cell 
receptor alpha gene locus (18). The SNPs are located between carnitine palmitoyl-
transferase 1B and choline kinase beta(19) and SNPs of purinergic receptor P2Y11(20).  
These genes may be involved in either cell death of orexin neurons or enhancing 
narcolepsy symptoms. Of note, the association with the T-cell receptor alpha locus 
might be important, as the interactions between HLA molecules on antigen presenting 
cells and T cell receptors on T cells play critical roles in self/non-self discrimination by 
the immune system(21). Recently, association between narcolepsy and  seasonal 
streptococcus, H1N1 infections and AS03-adjuvanted pH1N1 influenza vaccination was 
reported in Northern Europe and China(21). These observations further suggest the 
involvement of immunological mechanisms responsible for the loss of orexin-producing 
neurons. 
Each Receptor in Narcolepsy 
Detailed characterization of behavioral, pharmacological, and electrophysiological 
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features of orexin-/- and OX2R-/- mice showed that these mice exhibited two types of 
behavioral arrests.  One is “abrupt arrests”: a sudden loss of muscle tone during various 
active behaviors such as grooming and ambulation (9).  Detailed observations of 
behaviors during EEG/EMG recordings found that abrupt arrests in orexin-/- and OX2R-
/- mice are associated with EEG changes suggestive of unusual direct transitions from 
wakefulness to REM sleep. The other type are “gradual arrests”, which typically begin 
during quiet wakefulness and can be easily distinguished from the normal onset of 
resting behavior by the absence of stereotypic preparation for sleep (e.g., nesting and/or 
assumption of a curled or hunched posture, with limbs drawn under the body) and the 
presence of ratchet-like “nodding” of the head over a period of several seconds, with a 
transition to a collapsed posture. EEG/EMG correlates of the gradual arrests in both 
orexin-/- and OX2R-/- mice resemble transitions from wakefulness to non-REM sleep, 
suggesting this type is a counterpart of “sleep attacks” in human narcolepsy patients.  
In accordance with these similarities to clinical narcolepsy symptoms, “abrupt 
arrests” in orexin-/- mice were suppressed by systemic administration of clomipramine, 
a tricyclic anti-depressant drug used for the treatment of cataplexy, while administration 
of caffeine, a psychostimulant used to treat excessive sleepiness in human narcolepsy, 
tends to slightly increased abrupt arrest frequency. In clear contrast, systemic 
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administration of caffeine dose-dependently suppressed gradual arrests, while 
administration of clomipramine did not affect the frequency of gradual arrests in both 
orexin-/- and OX2R-/- mice. These observations suggest that the abrupt and gradual 
arrests are the presumptive mouse correlates of cataplexy and sleep attacks in human 
narcolepsy-cataplexy, respectively.   
  The International Working Group on Rodent Models of Narcolepsy proposed a 
consensus definition of murine cataplexy as; (i) an abrupt episode of nuchal atonia 
lasting at least 10 seconds. (ii) Theta activity dominates the EEG during the episode, 
and video recordings document immobility. (iii) at least 40 seconds of wakefulness must 
precede the episode (22). 
OX2R-/- mice have much less cataplexy than orexin-/- mice (31-fold lower 
frequency in OX2R-/- over orexin-/- mice), while they are similarly affected with sleep 
attacks. These results suggest that the normal regulation of wake/NREM sleep 
transitions depends critically on OX2R function, whereas the profound dysregulation of 
REM sleep control unique to the full narcolepsy-cataplexy syndrome emerges from loss 
of signaling through both OX1R- and OX2R-dependent pathways. 
 In pharmacological experiments, the effects of orexin-A on increasing 
wakefulness time and decreasing NREM sleep time were significantly attenuated in 
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both OX1R-/- and OX2R-/- mice as compared to wild-type mice, with substantially 
greater attenuation in OX2R-/- mice as compared with OX1R-/- mice. These results 
suggest that the OX2R pathway has a pivotal role in the promotion of wakefulness, but 
OX1R also plays additional roles in promoting arousal. Suppression of REM sleep by 
orexin-A administration was similarly attenuated in both OX1R -/- and OX2R -/- mice, 
suggesting a comparable contribution of both receptors to REM sleep suppression.  
 Histaminergic neurons in the TMN, which strongly expresses OX2R,  have been 
thought to play an important role in the arousal-promoting effect of orexin, because the 
effect of ICV orexin-A administration is markedly attenuated by the histamine H1 
receptor antagonist pyrilamine and is absent in H1 histamine receptor knockout 
mice(23, 24). Mochizuki et al. produced a mouse model in which a loxP-flanked gene 
cassette disrupts production of the OX2R, but normal OX2R expression can be restored 
by Cre recombinase(25). They showed that targeted Cre expression, i.e., focal 
restoration of OX2R expression, in the TMN and adjacent regions rescued 
fragmentation of wakefulness in this mouse model, suggesting that the orexin signaling 
mediated by OX2R in the TMN and/or its surrounding area in the posterior 
hypothalamus is sufficient to prevent sleepiness caused by systemic OX2R deficiency. 
However, orexins probably promote arousal through many redundant systems because 
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optogenetic activation of the orexin neurons still promotes wakefulness in mice lacking 
histamine, and mice lacking both OX1R and histamine H1 receptors demonstrate no 
abnormality in sleep/wakefulness(10). 
Clinically, narcolepsy can be divided into two pathological phenomena, 
suggesting that the pathophysiology of narcolepsy is caused by two mechanistically 
independent mechanisms. One is difficulty in maintaining long waking periods, 
characterized by abrupt transitions from wakefulness to NREM sleep (a failure to 
maintain long wake bouts). This phenomenon manifests clinically as excessive daytime 
sleepiness, which often results in sleep attacks, sometimes at socially inappropriate 
times. The aforementioned mouse studies suggest that it mostly results from a lack of 
Oxr-2 signaling(26). Psychostimulant drugs such as modafinil, methylphenidate, 
amphetamine and caffeine are used to treat these symptoms. The other key phenomenon 
is pathological intrusions of REM sleep into wakefulness (dysregulation of REM sleep 
onset); it is during these periods that patients experience cataplexy, hypnagogic 
hallucinations, and sleep paralysis. Therapies for these symptoms includes tricyclic 
antidepressants such as imipramine, serotonin/noradrenaline reuptake inhibitors (SNRI) 
and serotonin-specific reuptake inhibitors (SSRIs)(27), suggesting the existence of 
abnormal monoaminergic neurotransmission in the pathophysiology of cataplexy. As 
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described above, mouse studies have suggested that lack of signaling from both 
receptors seems to be critically associated with this symptom (9, 28), although we 
should take into account the species difference between mice and humans.  
The mechanisms through which the orexin receptors regulate sleep/wake 
behavior is further discussed in the article by Alexandre and Scammell.  
 
Chronic plastic changes in orexin-target neurons in narcolepsy 
Narcolepsy patients often suffer from insomnia in addition to excessive daytime 
sleepiness. Narcoleptic animals also show behavioral instability characterized by 
frequent transitions between all vigilance states, exhibiting very short bouts of NREM 
sleep as well as wakefulness(29). As already described, instability of wakefulness states 
in narcolepsy might be due to deficiency of orexin. However, the mechanism 
responsible for sleep instability in this disorder remains to be unknown. Because firing 
of orexin neurons ceases during sleep in healthy animals(30-32), deficiency of orexin 
does not explain abnormality of sleep. One  possible explanation is that chronic 
compensatory changes in target neurons of orexin in response to the progressive loss of 
endogenous orexin tone underlie the pathological regulation of sleep/wake states. In 
fact, we recently found that although 5-HT neurons showed almost normal firing 
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patterns according to behavioral states in narcoleptic orexin/ataxin-3 mice, NA neurons 
showed an altered firing pattern (our unpublished observation). NA neurons in 
orexin/ataxin-3 mice showed rather higher activity as compared with those in wildtype 
mice during both wakefulness and NREM sleep, especially in the early epoch of NREM 
sleep. We also found that the frequencies of sIPSCs and mIPSCs of NA neurons were 
markedly decreased in orexin/ataxin-3 mice as compared with wildtype mice, 
suggesting that the increase in firing rate of NA neurons might be due to synaptic 
downscaling  in GABAergic input to these cells. These observations suggest that 
GABAergic input to NA neurons might be altered in narcoleptic mice. The reduced 
GABAergic input might result from compensatory changes of GABAergic input with 
reduced net excitation to NA neurons due to loss of orexin neurons. These 
compensatory processes might explain why narcoleptics show an unstable NREM sleep 
state as well as unstable wakefulness state. 
 
Metabolic abnormalities in narcolepsy 
Narcolepsy patients have an increased body mass index (BMI) despite having 
decreased caloric intake (33, 34). Consistently, orexin neuron-ablated, orexin-ataxin 3 
mice display hypophagia and late-onset obesity, although the degree of abnormality 
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critically depends on the genetic backgrounds of mice (8, 35). Under normal conditions, 
the orexin system is likely to positively regulate feeding as well as arousal, activity, and 
basal energy expenditure, leading to increased energy expenditure, and this might 
explain why narcoleptic mice and humans show increased body weight. 
Transgenic mice with ubiquitous orexin overexpression are resistant to high-fat 
diet-induced obesity and insulin insensitivity through promotion of energy expenditure 
and reduced consumption (36). Genetic and pharmacological studies indicate that 
OX2R (rather than OX1R) signaling predominantly mediates this phenotype through 
negative energy homeostasis and improved leptin sensitivity. 
 
Therapeutic potential of drugs that target the orexin receptors 
Because orexin is a potent arousal promoting factor, it is reasonable to hypothesize that 
orexin receptor antagonists will be effective as drugs for insomnia treatment. To date, 
several orexin receptor antagonists with different pharmacological characteristics have 
been developed (Table 1). Because the two orexin receptors may have partly 
overlapping yet partly distinct physiological roles, pharamacological profiles of these 
antagonists are of importance. 
A dual orexin receptor antagonist , almorexant (ACT-078573, Actelion 
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Pharmaceuticals Ltd.) blocks both OXR-1 and OXR-2 with similar potency (IC50 16 
and 15 nM, respectively). Almorexant was reported to shorten time spent awake and 
enables and maintains sleep in rats, dogs, and humans (37, 38). Almorexant 
significantly improved the primary parameter of sleep efficiency (time spent sleeping 
while confined to bed during an eight hour period at night) in a dose-dependent 
manner. Almorexant decreased the latency to sleep onset and the number of wake bouts 
after sleep onset. Importantly, almorexant not only changed these physiological sleep 
parameters, but also significantly improved subjective sleep quality. Effective doses or 
even higher doses of almorexant did not cause any significant negative effects on next-
day performance (assessed by fine motor testing and mean reaction time). In addition, it 
was reported that rats administered high doses of almorexant (300 mg/kg, p.o.) are fully 
capable of spatial and avoidance learning(39). Notably, almorexant was well tolerated 
with no signs of cataplexy, suggesting that acute, short-lived, intermittent temporary 
blockade of orexin receptors will not result in a narcolepsy-like phenotype(40).  
Several other promising dual orexin receptor antagonists (DORA) and OXR2-
selective antagonists (SORA) are under development as sleep-inducers. Especially, MK-
4305 (suvorexant) is expected to be available in the clinic in 2014. 
Recently, repeated administration of an OXR-2 selective antagonist, JNJ-
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10397049, was shown to decrease the latency for persistent sleep and increased NREM 
sleep time more potently than did the dual antagonist, almorexant(41), while, an OXR-1 
selective antagonist SB-408124 had no effect on sleep parameters. Rather, the OXR-1 
antagonist attenuated the sleep-promoting effects of the OXR-2 antagonist when 
simultaneously administered, possibly by increasing dopamine release in the prefrontal 
cortex. On the other hand, another report suggested that a DORA is more effective for 
sleep promotion than antagonism of either receptor alone (42). Further research using 
selective antagonists is required to conclude the effectiveness, advantages and 
disadvantages of these compounds. 
Because narcolepsy results from the absence of orexins, replacement therapy 
using orexin receptor agonists or allosteric stimulators of orexin receptors could be 
promising ways for treating narcolepsy. This is supported by a study demonstrating that 
chronic overproduction of orexin from an ectopically expressed transgene effectively 
prevented the development of narcolepsy symptoms in orexin neuron-ablated 
(orexin/ataxin-3-transgenic) mice(43). Acute intracerebroventricular (ICV) 
administration of orexin A also maintained wakefulness, suppressed sleep, and 
completely inhibited cataplectic attacks in orexin/ataxin-3 mice(43).  
 However, chronic overexpression of orexin A in an unregulated fashion results 
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in fragmentation of NREM sleep (44), suggesting it would be beneficial for 
therapeutically relevant orexin agonists to have a short half-life (<12 hr). 
Enhancers of orexin receptor signaling, especially those acting on OX2R, may 
be also beneficial as a novel medication for daytime sleepiness caused by reasons other 
than narcolepsy. In the case of agonists/enhancers, however, the potential risk of 
addiction should be considered, since orexin signaling potentiates the mesolimbic 
dopamine pathway. At any rate, orexin receptors would provide promising targets for 
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Figure Legends 
Fig. 1. CSF orexin A levels in narcolepsy and control subjects. (A) CSF orexin A level is 
undetectably low in most narcolepsy patients (84.2%). Note that two HLA DQB1*0602-negative and 
one familial case have normal or high CSF orexin A levels. (B) Preproorexin transcripts are detected 
in the hypothalamus of a control (b) but not a narcolepsy subject (a). Melanin-concentrating 
hormone (MCH) transcripts are detected in the same region in both control (d) and narcolepsy (c)  f, 
fornix. Scale bar represents 10 µm (a–d) (Modified from Sakurai and Nishino, Orexin (Hypocretin) 





  Affinity  Units Ref 
 Compound OXR-1 OXR-2   
DORA ACT-078573 (almorexant) 7.9 (human), 7.8 
(rat) 
8.1 (human), 7.8 
(rat) 
pIC50 (37) 
DORA MK-4305 (suvorexant) 9.26 9.46 pKi (45) 
1-SORA SB-410220 7.7 nd pKi (46) 
1-SORA SB-334867 7.2 nd pKi (46) 
1-SORA SB-408124 7 nd pKi (46) 
1-SORA [3H]SB-674042 8.3 nd pKd (46) 
1-SORA SB-410220 8.1 6.3 pKb (46) 
1-SORA SB-334867 7.4 5.7 pKb (47) 
1-SORA SB-408124 7.7 5.9 pKb (46) 








5.3 – 5.8 8.0 – 8.6 pKi (48) 
Table 1 Available orexin receptor antagonists. 1-SORA, single orexin receptor antagonist, slective for OX1R; 2-
SORA, single orexin receptor antagonist, slective for OX2R;DORA, dual orexin receptor antagonist 
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Table. 2 Animal Models of Narcolepsy 
strain  phenotype Abnormality in orexin system 
dog familial Cataplexy, sleep/wake fragmentation Mutation in orexin type2 receptor 
 sporadic Cataplexy, sleep/wake 
fragmentation(severe) 






Behavioral arrest (cataplexy),  
sleep/wake fragmentation(severe) 
direct transition of wakefulness to REM 
sleep 
 
 OX1R KO sleep/wake fragmentation(mild)  
 OX2R KO Behavioral arrest (cataplexy),  




Behavioral arrest (cataplexy),  
sleep/wake fragmentation(severe) 
direct transition of wakefulness to REM 
sleep 






direct transition of wakefulness to REM 
sleep 
CSF orexin (-) 
(Loss of orexin neurons) 
 familial cataplexy 
sleep/wake fragmentation(severe) 
direct transition of wakefulness to REM 
sleep 
CSF orexin (-) 
 De novo 
mutant 
Early onset, severe cataplexy CSF orexin (-) 
Point mutation in the prepro-orexin 
gene (signal peptide) 
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